Clinical trials
Recruiting Small Cell Lung Carcinoma trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
216 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2005 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 5 |
| 2021 | 3 |
| 2022 | 13 |
| 2023 | 24 |
| 2024 | 40 |
| 2025 | 57 |
| 2026 | 61 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 216 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sichuan Baili Pharmaceutical Co., Ltd. | 6 |
| Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 6 |
| Memorial Sloan Kettering Cancer Center | 5 |
| National Cancer Institute (NCI) | 5 |
| Shanghai Pulmonary Hospital, Shanghai, China | 5 |
| Boehringer Ingelheim | 4 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 4 |
| Shanghai Chest Hospital | 4 |
| Amgen | 3 |
| Novartis Pharmaceuticals | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Small Cell Lung Carcinoma | 216 |
| Carcinoma, Non-Small-Cell Lung | 51 |
| Lung Neoplasms | 35 |
| Ovarian Neoplasms | 15 |
| Colorectal Neoplasms | 14 |
| Endometrial Neoplasms | 13 |
| Triple Negative Breast Neoplasms | 13 |
| Carcinoma, Renal Cell | 12 |
| Squamous Cell Carcinoma of Head and Neck | 12 |
| Uterine Cervical Neoplasms | 12 |
Trials
Showing 1 to 25 of 216. Each trial links to its page on Pharma Observatory.
116 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.